Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand

Laura A. Solt, Naresh Kumar, Philippe Nuhant, Yongjun Wang, Janelle L. Lauer, Jin Liu, Monica A. Istrate, Theodore M. Kamenecka, William R. Roush, Dušica Vidović, Stephan C. Schürer, Jihong Xu, Gail Wagoner, Paul D. Drew, Patrick R. Griffin, Thomas P. Burris

Research output: Contribution to journalArticle

296 Citations (Scopus)

Abstract

T-helper cells that produce interleukin-17 (TH 17 cells) are a recently identified CD4+ T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors Î ± and Î 3t (RORÎ ± and RORÎ 3t, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both ROR ± and ROR 3t and which inhibits TH 17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of RORÎ ± and ROR 3t, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors-™ transcriptional activity. SR1001 inhibited the development of murine TH 17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human TH 17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors ROR ± and RORÎ 3t to inhibit specifically TH 17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)491-494
Number of pages4
JournalNature
Volume472
Issue number7344
DOIs
StatePublished - Apr 28 2011

Fingerprint

Th17 Cells
Autoimmunity
Ligands
Autoimmune Diseases
Interleukin-17
Cell Differentiation
Co-Repressor Proteins
Retinoic Acid Receptors
T-Lymphocyte Subsets
Cytoplasmic and Nuclear Receptors
Helper-Inducer T-Lymphocytes
SR1001
Cytokines
Gene Expression
Proteins

ASJC Scopus subject areas

  • General

Cite this

Solt, L. A., Kumar, N., Nuhant, P., Wang, Y., Lauer, J. L., Liu, J., ... Burris, T. P. (2011). Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand. Nature, 472(7344), 491-494. https://doi.org/10.1038/nature10075

Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand. / Solt, Laura A.; Kumar, Naresh; Nuhant, Philippe; Wang, Yongjun; Lauer, Janelle L.; Liu, Jin; Istrate, Monica A.; Kamenecka, Theodore M.; Roush, William R.; Vidović, Dušica; Schürer, Stephan C.; Xu, Jihong; Wagoner, Gail; Drew, Paul D.; Griffin, Patrick R.; Burris, Thomas P.

In: Nature, Vol. 472, No. 7344, 28.04.2011, p. 491-494.

Research output: Contribution to journalArticle

Solt, LA, Kumar, N, Nuhant, P, Wang, Y, Lauer, JL, Liu, J, Istrate, MA, Kamenecka, TM, Roush, WR, Vidović, D, Schürer, SC, Xu, J, Wagoner, G, Drew, PD, Griffin, PR & Burris, TP 2011, 'Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand', Nature, vol. 472, no. 7344, pp. 491-494. https://doi.org/10.1038/nature10075
Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J et al. Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011 Apr 28;472(7344):491-494. https://doi.org/10.1038/nature10075
Solt, Laura A. ; Kumar, Naresh ; Nuhant, Philippe ; Wang, Yongjun ; Lauer, Janelle L. ; Liu, Jin ; Istrate, Monica A. ; Kamenecka, Theodore M. ; Roush, William R. ; Vidović, Dušica ; Schürer, Stephan C. ; Xu, Jihong ; Wagoner, Gail ; Drew, Paul D. ; Griffin, Patrick R. ; Burris, Thomas P. / Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand. In: Nature. 2011 ; Vol. 472, No. 7344. pp. 491-494.
@article{ffdd0e9e9dc24cf7bd12fe8fc1b7affb,
title = "Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand",
abstract = "T-helper cells that produce interleukin-17 (TH 17 cells) are a recently identified CD4+ T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors {\^I} ± and {\^I} 3t (ROR{\^I} ± and ROR{\^I} 3t, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both ROR ± and ROR 3t and which inhibits TH 17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of ROR{\^I} ± and ROR 3t, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors-™ transcriptional activity. SR1001 inhibited the development of murine TH 17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human TH 17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors ROR ± and ROR{\^I} 3t to inhibit specifically TH 17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.",
author = "Solt, {Laura A.} and Naresh Kumar and Philippe Nuhant and Yongjun Wang and Lauer, {Janelle L.} and Jin Liu and Istrate, {Monica A.} and Kamenecka, {Theodore M.} and Roush, {William R.} and Dušica Vidović and Sch{\"u}rer, {Stephan C.} and Jihong Xu and Gail Wagoner and Drew, {Paul D.} and Griffin, {Patrick R.} and Burris, {Thomas P.}",
year = "2011",
month = "4",
day = "28",
doi = "10.1038/nature10075",
language = "English (US)",
volume = "472",
pages = "491--494",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7344",

}

TY - JOUR

T1 - Suppression of TH 17 differentiation and autoimmunity by a synthetic ROR ligand

AU - Solt, Laura A.

AU - Kumar, Naresh

AU - Nuhant, Philippe

AU - Wang, Yongjun

AU - Lauer, Janelle L.

AU - Liu, Jin

AU - Istrate, Monica A.

AU - Kamenecka, Theodore M.

AU - Roush, William R.

AU - Vidović, Dušica

AU - Schürer, Stephan C.

AU - Xu, Jihong

AU - Wagoner, Gail

AU - Drew, Paul D.

AU - Griffin, Patrick R.

AU - Burris, Thomas P.

PY - 2011/4/28

Y1 - 2011/4/28

N2 - T-helper cells that produce interleukin-17 (TH 17 cells) are a recently identified CD4+ T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors Î ± and Î 3t (RORÎ ± and RORÎ 3t, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both ROR ± and ROR 3t and which inhibits TH 17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of RORÎ ± and ROR 3t, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors-™ transcriptional activity. SR1001 inhibited the development of murine TH 17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human TH 17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors ROR ± and RORÎ 3t to inhibit specifically TH 17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.

AB - T-helper cells that produce interleukin-17 (TH 17 cells) are a recently identified CD4+ T-cell subset with characterized pathological roles in autoimmune diseases. The nuclear receptors retinoic-acid-receptor-related orphan receptors Î ± and Î 3t (RORÎ ± and RORÎ 3t, respectively) have indispensible roles in the development of this cell type. Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both ROR ± and ROR 3t and which inhibits TH 17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of RORÎ ± and ROR 3t, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors-™ transcriptional activity. SR1001 inhibited the development of murine TH 17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human TH 17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors ROR ± and RORÎ 3t to inhibit specifically TH 17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.

UR - http://www.scopus.com/inward/record.url?scp=79955526989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955526989&partnerID=8YFLogxK

U2 - 10.1038/nature10075

DO - 10.1038/nature10075

M3 - Article

VL - 472

SP - 491

EP - 494

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7344

ER -